|
WO2021055576A1
|
|
Combination of modafinil and an ampakine for improving cognition
|
|
WO2020157691A1
|
|
Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
|
|
US2020138805A1
|
|
Compositions and methods for opioid antagonist delivery
|
|
WO2019231993A1
|
|
Compositions and methods for opioid overdose rescue
|
|
US2020345726A1
|
|
Sleep disorder treatment and prevention
|
|
AU2018390826A1
|
|
Abuse deterrent morphine sulfate dosage forms
|
|
US2020385487A1
|
|
Humanized antibodies targeting human tissue factor
|
|
US2020155471A1
|
|
Methods and compositions particularly for treatment of attention deficit disorder
|
|
WO2019079729A1
|
|
Pharmaceutical dosage forms
|
|
US2020289424A1
|
|
Pharmaceutical compositions comprising delayed release gelling agent compositions
|
|
EP3675842A1
|
|
Pharmaceutical dosage forms
|
|
AU2018291397A1
|
|
Method of treatment and dosage forms thereof
|
|
US2019330208A1
|
|
Morphinan derivatives and use thereof
|
|
KR20190029682A
|
|
Treatment and prevention of sleep disorders
|
|
US2019201410A1
|
|
Trace amine associated receptor 1 agonists and partial agonists for pain treatment
|
|
CN109071518A
|
|
Oxazoline vacation dimer, medical composition and its use
|
|
US2019084942A1
|
|
Process for preparing substituted 9,10-dioxo-9,10-dihydroanthrecenes and 6H-anthra[1,9-cd]isoxazol-6-ones
|
|
US2018370926A1
|
|
Process of preparing tyrosine kinase inhibitor
|
|
CN107613965A
|
|
For reducing the method and composition of gastric emptying
|
|
WO2016090158A1
|
|
6.7-cyclicmorphinan derivatives and use thereof
|
